A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with Covid-19 is to restart after being approved by British regulators.
Swiss pharmaceuticals giant Novartis has decided to halt a clinical trial of hydroxychloroquine as a treatment for Covid-19, citing problems in recruiting enough patients for the study of the controversial drug.
British scientists halted a large trial on Monday that had been exploring the use of the anti-malaria drug hydroxychloroquine in patients with the pandemic disease Covid-19 after initial results showed no evidence of benefit.
Dozens of scientists have raised concerns over a large-scale study of hydroxychloroquine and chloroquine published in the Lancet that led to the World Health Organization suspending clinical trials of the anti-viral drugs
Malaria drug hydroxychloroquine, which US President Donald Trump says he has been taking, is tied to increased risk of death in Covid-19 patients, according to a study published in medical journal Lancet.
Chloroquine and Hydroxychloroquine, drugs used for a very long time to treat malaria, are promising for the treatment and prevention of the novel coronavirus (Covid-19), an expert with the Qatar Biomedical Research..
India said on Wednesday it had banned the export of hydroxychloroquine and formulations of the malaria drug while experts test its efficacy in helping treat patients infected with coronavirus.